cytokine
Overview
Cytokines are signaling proteins that cells use to instruct one another, chiefly in immunity, inflammation, differentiation and tissue repair. They are typically secreted and act over short distances, in autocrine fashion on the producing cell or paracrine fashion on its neighbors, though some — interleukin-6 among them — reach concentrations that act systemically, and others exist in cell-associated form: membrane-bound tumor necrosis factor signals on contact and can transmit a signal back into the cell that bears it. The category is functional rather than structural, spanning interleukins, interferon species, tumor necrosis factors, colony-stimulating factors and the chemokines, which differ from the rest in that they act as concentration gradients that direct where leukocytes move rather than what they do.
Signaling runs through a few receptor architectures, and this is what makes the system druggable. Type I and II cytokine receptors have no intrinsic catalytic activity and rely on associated Janus kinases to phosphorylate STAT transcription factors; the interleukin-1 and Toll-like receptor family converge on MyD88 to activate NF-κB; and the tumor necrosis factor receptor superfamily recruits TRAF adaptors that branch toward either inflammation or cell death. Three properties follow and complicate every attempt to reason about a single cytokine: pleiotropy, since one cytokine acts differently on different cells; redundancy, since several produce the same effect, which is why blocking one often achieves less than expected; and strong synergy or antagonism in combination. Function is set by context rather than by identity — Transforming growth factor beta (TGF-β) is immunosuppressive in one setting and fibrogenic in another.
The balance between pro-inflammatory mediators such as TNF-α and IL-1β and regulators such as IL-10 and TGF-β maintains homeostasis, and its loss underlies chronic inflammation, autoimmunity, malignancy and neurodegeneration; acute, uncontrolled release produces the cytokine storm seen in sepsis, severe infection and after some cell therapies. Both directions are exploited therapeutically. Blocking agents — TNF inhibitors, IL-6 receptor and IL-17 antibodies, and Janus kinase inhibitors that cut off whole receptor families at once — are mainstays in rheumatology, dermatology and gastroenterology, while cytokines themselves are given as drugs, including interferons in multiple sclerosis and viral hepatitis and colony-stimulating factors after chemotherapy. Because the same molecules that mediate disease also run normal host defense, immunosuppression and infection risk are the shared, mechanism-based cost of blockade.
Recent Publications Summary
Cytokines function as key biomarkers and therapeutic targets across diverse clinical contexts. In autoimmune encephalitis, cytokine profiling alongside other inflammatory markers such as neurofilament light chain and glial fibrillary acidic protein in cerebrospinal fluid and serum samples provides diagnostic and prognostic utility, with cytokines measured as part of comprehensive inflammatory panels during baseline assessment and longitudinal follow-up 42546229Aug. Within the tumor microenvironment, TGF-β exemplifies a critical cytokine axis in pancreatic cancer; this pro-tumoral cytokine is essential for regulatory T cell development and maintenance, and selective inhibition of the αvβ5 integrin-mediated TGF-β activation depletes Tregs by depriving them of this cytokine signal, thereby enhancing anti-tumor immunity 42133398May. Systemic cytokine dysregulation occurs in chronic kidney disease, where aberrant cytokine profiles correlate with reduced sexual function in female patients, implicating broader endocrine and inflammatory dysfunction 42390260Jul. Stability and preservation of cytokine bioactivity are important for therapeutic applications; serum cytokines intended for therapeutic use in allogeneic serum eye drops undergo rigorous stability assessment using high-resolution immunoassays such as Luminex multiplex bead-based technology 42335573Jun.
Emerging therapeutic strategies harness cytokines for tissue regeneration. ATP-responsive injectable DNA hybrid hydrogels have been engineered to achieve controlled, on-demand release of fibroblast growth factor 21 (FGF-21), a pleiotropic metabolic cytokine, to promote muscle regeneration and recovery 42336011Jun. Conversely, neutralization of pathogenic pro-inflammatory cytokines represents a key immunomodulatory strategy; reverse-engineered lipid nanoparticle exploit protein corona formation to sequester and neutralize multiple pro-inflammatory mediators simultaneously, offering a multimodal approach to cytokine sequestration rather than targeting single cytokine axes 42522898Jul. In cancer immunotherapy, interleukin-18 (IL-18), a pro-inflammatory cytokine released following microwave ablation of osteosarcoma, enhances anti-tumor immunity by promoting dendritic cell function and CD8+ T cell infiltration 42398970Jul. Traditional medicinal approaches modulate disease-associated cytokine imbalances; Taohong Siwu Decoction suppresses pro-inflammatory and neurotoxic cytokine markers (TNF-α, iNOS) while promoting anti-inflammatory and neuroprotective factors (IL-10, TGF-β) in astrocytes following ischemic stroke, facilitating oligodendrocyte maturation and remyelination 41962609Apr.
What Changes, What Holds
1. Cytokine profiling is becoming a practical biomarker layer in disease assessment and monitoring
NEW DIRECTION Cytokines are no longer just mechanistic mediators here; they are being used as part of broader inflammatory panels for diagnosis, prognosis, and longitudinal follow-up, which extends the baseline role of cytokines into routine clinical stratification. The same paragraph also reinforces their value as therapeutic targets, while adding a caution that assay stability and preservation of bioactivity matter for any cytokine-based product or measurement strategy 42546229Aug42335573Jun.
2. Cytokine biology is being leveraged for regeneration and multimodal immunomodulation
NEW DIRECTION ATP-responsive release of FGF-21 and cytokine sequestration by engineered lipid nanoparticle broaden cytokines beyond the baseline account of immune regulation and inflammation into controlled regenerative delivery and broad-spectrum neutralization strategies. The IL-18 and Taohong Siwu Decoction findings also fit the established view that cytokines shape anti-tumor and post-injury responses, but they sharpen the therapeutic logic: some cytokines are being amplified for repair, while others are being suppressed or trapped to reduce pathology 42336011Jun42522898Jul.
Overview update candidates: cytokine profiling as a diagnostic/prognostic biomarker and the need for stability-preserving assays in therapeutic applications; controlled cytokine delivery for tissue regeneration and multimodal cytokine sequestration as therapy.
cytokine
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding cytokine are described as follows:
- Alzheimer's disease (Disease) — 3 papers: PMIDs 42440182, 42332435, 42166973
- inflammation (Biological Process) — 3 papers: PMIDs 42409068, 42383709, 42345095
- T-lymphocytes (Cellular Component) — 3 papers: PMIDs 42409068, 41941337, 41560593
- atopic dermatitis (Disease) — 2 papers: PMIDs 42413573, 42394466
- dendritic cell (Cellular Component) — 2 papers: PMIDs 41941337, 41560593
- human gut flora (Biological Process) — 2 papers: PMIDs 42418046, 41560593
- lipid nanoparticles (Technology) — 2 papers: PMIDs 42522898, 42474084
- multiple sclerosis (Disease) — 2 papers: PMIDs 42332435, 41956308
- Neuroinflammation (Biological Process) — 2 papers: PMIDs 42409068, 42166973
- neuronitis (Clinical Metric) — 2 papers: PMIDs 42418046, 41871474
- regulatory T cell (Cellular Component) — 2 papers: PMIDs 42345095, 42103027
- acne (Disease) — 1 paper: PMIDs 42359722
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study cytokine:
- western blot (Technology) — 6 papers: PMIDs 42418046, 42394466, 42283639, 42166973, etc.
- ELISA (Technology) — 5 papers: PMIDs 42418053, 42394466, 42335573, 42166973, etc.
- flow cytometry (Technology) — 4 papers: PMIDs 42400303, 42394466, 42345095, 42260632
- Human umbilical vein endothelial cell (Cellular Component) — 3 papers: PMIDs 42097773, 41936840, 41936260
- lipopolysaccharide (Other) — 3 papers: PMIDs 42522898, 42345095, 42166973
- proinflammatory cytokine (Biological Process) — 3 papers: PMIDs 42443654, 42387611, 41974235
- astrocyte (Cellular Component) — 2 papers: PMIDs 42166973, 41962609
- Hippocampus (Organism) — 2 papers: PMIDs 42440182, 42418046
- Immunofluorescence (Technology) — 2 papers: PMIDs 42166973, 41962609
- macrophage (Cellular Component) — 2 papers: PMIDs 42264056, 41974235
- molecular docking (Technology) — 2 papers: PMIDs 42166973, 41894851
- Morris water navigation task (Technology) — 2 papers: PMIDs 42418046, 42166973
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to cytokine include:
- Toll-like receptor 4 (TLR4) (Protein) — 2 papers: PMIDs 42475333, 41936260
- transforming growth factor-β (TGF-β) pathway (Pathway) — 2 papers: PMIDs 42260632, 42133398
- (+)-taxifolin (Chemical) — 1 paper: PMIDs 42097773
- Acetylcholinesterase (AChE) (Protein) — 1 paper: PMIDs 41871474
- AGE-RAGE/NF-κB signaling axis (Pathway) — 1 paper: PMIDs 41936840
- Al-CpG (Chemical) — 1 paper: PMIDs 42103027
- Alpha-v Beta-5 Integrin (Protein) — 1 paper: PMIDs 42133398
- Antenne 2 (Biological Process) — 1 paper: PMIDs 41962609
- anti-inflammation (Other) — 1 paper: PMIDs 41782615
- anti-programmed cell death protein 1 (Therapy) — 1 paper: PMIDs 42398970
- attenuation parameters (K, A1) (Other) — 1 paper: PMIDs 41962609
- Butyrylcholinesterase (BCHE) (Protein) — 1 paper: PMIDs 41871474
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with cytokine include:
- proinflammatory cytokine (Biological Process) — 19 papers: PMIDs 42443654, 42418053, 42418046, 42413573, etc.
- Tumor necrosis factor-α (TNF-α) (Protein) — 12 papers: PMIDs 42443654, 42418053, 42401089, 42400869, etc.
- Th2 cytokines (Protein) — 9 papers: PMIDs 42443654, 42394466, 42359722, 42114716, etc.
- Interleukin-1β (IL-1β) (Protein) — 4 papers: PMIDs 42474084, 42401089, 42390648, 42383709
- Caspase-1 (CASP1) (Protein) — 3 papers: PMIDs 42418046, 42394466, 42114716
- Staphylococcus aureus (Organism) — 3 papers: PMIDs 42413573, 42383709, 42097773
- systemic inflammation (Disease) — 3 papers: PMIDs 42522898, 42401089, 42166973
- TXNIP/NLRP3 pathway (Pathway) — 3 papers: PMIDs 42418046, 42394466, 41894850
- Allograft inflammatory factor 1 (Gene) — 2 papers: PMIDs 42418046, 41871474
- biocompatibility (Other) — 2 papers: PMIDs 42390648, 42336011
- C-X-C motif chemokine ligand 8 (CXCL8) (Protein) — 2 papers: PMIDs 42413573, 42394466
- CD8-positive T-cell (Cellular Component) — 2 papers: PMIDs 42260632, 42133398
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding cytokine are summarized below:
- immunotherapy (Therapy) — 2 papers: PMIDs 42133398, 41560593
- therapeutic target (Other) — 2 papers: PMIDs 42409068, 42345095
- 5-HT receptor (Protein) — 1 paper: PMIDs 42443654
- acne repair phase (Biological Process) — 1 paper: PMIDs 42359722
- acne treatment strategy (Other) — 1 paper: PMIDs 42359722
- affinity ligand (Other) — 1 paper: PMIDs 42133398
- allergic diseases (Disease) — 1 paper: PMIDs 42103027
- Alpha-v Beta-5 Integrin (Protein) — 1 paper: PMIDs 42133398
- Amyloid beta generation (Biological Process) — 1 paper: PMIDs 42166973
- anti-tumor and anti-inflammatory agents (Other) — 1 paper: PMIDs 41894850
- antileishmanial effects (Other) — 1 paper: PMIDs 41812425
- ATC code L04 (Therapy) — 1 paper: PMIDs 42400303